In 1962 brucellosis in yeast probiotics was first used as a prescription drug to treat diarrhea in humans. Currently, Saccharomyces brassi is used in more than 80 countries in Europe, North and South America and Asia. Numerous guidelines affirm the role of bradellosis probiotics in alleviating diarrhea.

Yeast probiotics are larger than lactobacillus probiotics (about 10 times larger than lactobacillus probiotics) and are more likely to create a mass effect in the gut. Also, yeast probiotics are not affected by antibiotics.

Angel nutrition research team has developed a patented strain of yeast probiotics (BldD-3) and innovative production technology after years of research.